COMMUNIQUÉS West-GlobeNewswire

Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product
15/06/2026
SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ CUPR ” or “the Company ”), a biomedical company developing and marketing products for the chronic wounds, infertility, [...]
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
15/06/2026
Company at a Turning Point — Moving the Business to a Different Level, With Growing Revenue and a Roadmap Toward Improved Profitability CHICAGO, June 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or [...]
KFSH Highlights Provider Transformation Through Measurable Operational Impact at HLTH Europe 2026
15/06/2026
AMSTERDAM, June 15, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) is bringing a practical provider-transformation message during its participation at HLTH Europe 2026, taking [...]
Porosome Therapeutics Announces Global Drug Development Partnership with the Largest Governmental R&D Organization in India
15/06/2026
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Porosome Therapeutics, Inc., announced today that it has entered into a drug development partnership with the Council of Scientific and Industrial Research (CSIR) of the [...]
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
15/06/2026
ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as [...]
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
15/06/2026
Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 [...]
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
15/06/2026
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, [...]
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
15/06/2026
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function Raanana, Israel [...]
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
15/06/2026
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussions Additional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury [...]
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
15/06/2026
Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution RENO, Nev., June 15, 2026 (GLOBE NEWSWIRE) -- [...]
Sienna Announces June Dividend
15/06/2026
MARKHAM, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
15/06/2026
Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX’s platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including [...]
BVI Expands Commitment to Ophthalmic Education with New Experience Hub in Europe
15/06/2026
New facility expands opportunities for hands-on learning, professional development, and clinical collaboration. BVI plans to expand the Hub's educational offerings through structured programs covering cataract surgery, [...]
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
15/06/2026
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery [...]
AI is changing what is possible in the $10 trillion food industry. Anterra Capital is backing what comes next.
15/06/2026
Specialist food and agriculture investor announces $100 million first close of Fund III as the sector enters the most attractive deployment moment in twelve years. Boston, Massachusetts and Amsterdam, Netherlands, June [...]
ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea
15/06/2026
Integration supports remote patient monitoring and value-based care SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“ [...]
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
15/06/2026
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today [...]
XBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active
15/06/2026
La demande d’IND pour l’étude V-SPINE a fait l’objet d’un examen de 30 jours par la FDA sans suspension clinique, ouvrant ainsi la voie au recrutement de patients aux États-Unis AUSTIN, Texas, 15 juin 2026 (GLOBE [...]
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
15/06/2026
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a [...]

Pages